Skip to main content

Table 1 HLA class I genotyping results of the 74 cell lines used in the study

From: Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Origin Cell line A Locus B Locus Cw Locus Origin Cell line A Locus B Locus Cw Locus
Lung A549 25, 30 18, 44 12, 16 Liver Huh 7.5.1 11 54 1
  $ A549 p107 25, 30 18, 44 12, 16 Melanoma *$ 1858-MEL 01, 24 52, 55 01, 12
  EKVX 1 37 6   #$ 1936-MEL 3 15/95, 4901 02, 07
  HOP 92 03, 24 27, 47 01, 06   397-MEL 01, 25 08, 15/95 04, 07
  # HOP62 03, 11 40, 56 01, 03   *$888-MEL 01, 24 52, 55 01, 12
  *$ NCI-H1299 24 14 8   *A375 01, 02/92 44, 57 06, 16
  NCI-H226 01, 24 07, 39 07, 12   LOX-IMVI 11, 29 07, 44 07, 16
  NCI-H23 8001 50 6   M14 11, 24 15/95, 35 03, 04
  NCI-H322M 29 44 16   SK-MEL-2 03, 26 35, 38 04, 12
  NCI-H460 24, 68 35, 51 03, 15   SK-MEL-28 11 40 3
  NCI-H522 02/92 44, 55 03, 05   #SK-MEL-5 02/92, 32 39, 44 05, 12
Cervix *Siha 24 40 3   #UACC-257 01, 32 08, 40 07, 15
CNS SF-268 01, 32 08, 40 02, 07   # UACC-62 02/92, 11 07, 40 03, 07
  SF-295 01, 26 07, 55 03, 07 Ovarian IGR-OV1 24, 33 49 7
  SF-539 02/92 08, 35 04, 07   NCI/ADR-RES 01, 25 57 6
  SNB-19 02/92 18 5   OVCAR-3 02/92, 29 07, 58 7
  SNB-75 02/92, 11 35, 39 04, 12   OVCAR-3 p7 02/92, 29 07, 58 7
  U251 02/92 18 5   # OVCAR-4 02/92 18, 44 05, 07
Colon COLO 205 01, 02/92 07, 08 7   OVCAR-5 01, 02/92 08, 44 05, 07
  HCC 2998 02/92, 24 37, 40 04, 06   OVCAR-8 01, 25 57 6
  HCT-116 01, 02/92 18, 45 05, 07   SK-OV-3 03, 68 18, 35 04, 05
  HCT-15 02/92, 24 08, 35 04, 07 Pancreas *$ MIA Paca2 24, 32 40, 40 2
  HT-29 01, 24 35, 44 4   *$ Panc 1 02/92, 11 38 12
  $ HT-29 p155 01, 24 35, 44 4 Renal 786-0 3 07, 44 05, 07
  KM12 02/92 7 7   A498 02/92 8 7
  SW-620 02/92, 24 07, 15/95 7   ACHN 26 49 7
Breast BT-549 01, 02/92 1517, 55 03, 07   # CAKI-1 02/92, 24 37, 40 04, 06
  *$GI-101A 29 07, 08 07, 15   RXF 393 02,24 1444 50,802
  # HS-578T 03, 11 40, 56 01, 03   SN12C 03, 24 07, 44 05, 07
  MCF-7 02/92 18, 44 5   TK-10 33 14 8
  $ MDA-MB-231 p41 02/92 40, 41 02, 17   UO-31 01, 03 07, 14 07, 08
  MDA-MB-231 p6 02/92 40, 41 02, 17 Hematopoietic CCRF-CEM 01, 31 08, 40 03, 07
  MDA-MB-435 11, 24 15/95, 35 03, 04   HL-60 1 57 6
  T-47D 33 14 8   K-562 11, 31 18, 40 03, 05
Prostate $ DU-145 03, 33 50, 57 6   MOLT-4 01, 25 18, 57 06, 12
  PC-3 p35 01, 24 13, 55 01, 06   RPMI 8226 30,68 15,15 02.,03
  PC-3 p7 01, 24 13, 55 01, 06   SR 02/92, 03 37, 39 06, 12
  1. ($) Cell lines previously characterized by our group for their in vivo responsiveness to GLV - 1h68 oncolityc therapies [12].
  2. Among all cells lines, 58 (78.3%) matched previous genotyping results conducted in our lab, 8 (10.8%) had not been previously genotyped (*) and 8 cell lines (10.8%) displayed a different genotype from our previous genotyping (#) [20].